Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies
It is currently unclear which patients with breast cancer with sentinel lymph node (SLN) metastases do not need axillary lymph node dissection (ALND).
Patients and methods
A cohort of 1,132 women who had unilateral invasive breast cancer with clinically negative nodes or nodes suspicious for metastasis, were intraoperatively diagnosed as having negative SLNs, and did not undergo an immediate ALND. Our intraoperative histological investigation uses H&E staining of a frozen section from a maximum cut surface of each SLN. Of these 1,132 women, 132 (11.7%) were postoperatively diagnosed as having positive SLNs, which classifies them as having an intraoperative, false-negative SLN biopsy (SLNB). Patient and tumor characteristics, treatment methods, and the prognoses of these patients were investigated and compared with the remaining 1,000 patients who were negative for SLNB.
Of the 132 patients with intraoperative, false-negative SLNB, none underwent a further ALND. With a median follow-up period of 58.1 months, none of these patients exhibited recurrence in the axillary nodes. Their recurrence-free survival rates were not statistically different from those of patients with negative SLNB.
ALND can be avoided in most patients with breast cancer with intraoperative, false-negative SLNB.
KeywordsBreast cancer Sentinel lymph node biopsy (SLNB) Intraoperative false-negative SLNB Axillary lymph node dissection Recurrence
Axillary lymph node dissection
- IDC NOS
Invasive ducal carcinoma not otherwise specified
Isolated tumor cells
Sentinel lymph node
Sentinel lymph node biopsy
- 4.Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. National surgical adjuvant breast and bowel project, technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8:881–8.CrossRefPubMedGoogle Scholar
- 11.Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240:462–71.CrossRefPubMedGoogle Scholar
- 16.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.Google Scholar
- 17.Takei H, Kurosumi M, Yoshida T, Ninomiya J, shikawa Y, Hayashi Y, Tozuka K, Asakawa H, Oba H, Inoue K, Tabei T. Positive sentinel lymph node biopsy predicts the number of metastatic axillary nodes of breast cancer. Breast. 2009 [Epub ahead of print].Google Scholar
- 33.Spruit PH, Siesling S, Elferink MA, Vonk EJ, Hoekstra CJ. Regional radiotherapy versus an axillary lymph node dissection after lumpectomy: a safe alternative for an axillary lymph node dissection in a clinically uninvolved axilla in breast cancer. A case control study with 10 years follow up. Radiat Oncol. 2007;2:40.CrossRefPubMedGoogle Scholar
- 35.Galper S, Recht A, Silver B, Bernardo MV, Gelman R, Wong J, et al. Is radiation alone adequate treatment to the axilla for patients with limited axillary surgery? Implications for treatment after a positive sentinel node biopsy. Int J Radiat Oncol Biol Phys. 2000;48:125–32.CrossRefPubMedGoogle Scholar
- 38.European Organization for Research and Treatment of Cancer. Phase III randomized study of complete axillary lymph node dissection versus axillary radiotherapy in sentinel lymph node positive women with operable invasive breast cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00014612.